Key Takeaway: Precision BioSciences presented promising preclinical data for PBGENE-PMM at the Mitochondrial Medicine Therapeutic Development conference. The data showcased the ARCUS technology's capability to effectively eliminate mutant mitochondrial DNA without affecting nuclear DNA. This advancement could provide a new therapeutic option for patients with Primary Mitochondrial Myopathy.
Price reaction · baseline $11.73 (2024-03-18 close) · hit pre-market · 1 other DTIL headline(s) in the window, move may be shared
day 0 close · peak
+2.3%
Market Sentiment Analysis
POSITIVE FACTORS
Efficient elimination of mutant mitochondrial DNA demonstrated.
Potential therapy for Primary Mitochondrial Myopathy highlighted.
No nuclear off-target editing observed.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+24%
120-day peak, hindsight
Typical move
4.8%
average across 2 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Targeted CEA CAR-T
Phase 1 · Advanced Lung Cancer
Full Press Release Details
– Data presented at Mitochondrial Medicine Therapeutic Development (MMTD) annual conference demonstrated ARCUS’ ability to efficiently eliminate mutant mitochondrial DNA without nuclear off-target editing – PBGENE-PMM shifted heteroplasmy by eliminating mutant m.3243 mitochondrial DNA (mtDNA) while
Frequently Asked Questions
What is PBGENE-PMM?
PBGENE-PMM is a potential therapy developed by Precision BioSciences for Primary Mitochondrial Myopathy.
What technology does PBGENE-PMM utilize?
PBGENE-PMM utilizes ARCUS technology to eliminate mutant mitochondrial DNA.
What was the outcome of the preclinical data?
The data showed successful elimination of mutant m.3243 mitochondrial DNA without nuclear off-target effects.
Where was the data presented?
The data was presented at the Mitochondrial Medicine Therapeutic Development conference.